Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 43
Filter
Add more filters










Publication year range
1.
Article in English | MEDLINE | ID: mdl-29753211

ABSTRACT

N2-(4-Amino-cyclohexyl)-9-cyclopentyl-N6-(6-furan-2-yl-pyridine-3-ylmethyl)-9H-purine-2,6-diamine (BP-14) and 2-(5-{[2-(4-amino-cyclohexylamino)-9-cyclopentyl-9H-purine-6-ylamino]-methyl}-pyridine-2-yl)-phenol (BP-20) are novel cyclin-dependent kinase inhibitors, structurally related to roscovitine, with significant biological activity. A simple, selective and sensitive liquid chromatography - tandem mass spectrometry method for determining them in rat plasma, using roscovitine as an internal standard, was developed and validated. Chromatographic separation was performed in reversed phase mode on Acquity BEH C18 column (100 × 2.1 mm, 1.7 µm) by gradient elution with mobile phases composed of 15 mM ammonium formate pH 4.0 and methanol at flow rate 0.25 mL/min at 40 °C. The analytes were detected based on their characteristic multiple reaction monitoring transitions in positive electrospray ionization mode m/z 473.07 > 157.93 for BP-14, m/z 499.62 > 184.2 for BP-20 and m/z 355.5 > 90.86 for internal standard. In plasma the method provided good linearity within the entire concentration range: 1-10,000 nmol/L (r2 = 0.9989) for BP-14 and 10-25,000 nmol/L (r2 = 0.9994) for BP-20; the limit of detection was 0.6 nmol/L for BP-14 and 6.1 nmol/L for BP-20. Validation was also performed in bile and urine. The results of validation fit within the acceptance limits following European Medicines Agency guidelines. The method was applied in a pharmacokinetic study of BP-14 and BP-20 in vivo in rats following intravenous and intraduodenal administration including plasma pharmacokinetics, tissue distribution and excretion (renal and biliary). Both compounds showed low bioavailability after intraduodenal administration (0.630 and 1.58% for BP-14 and BP-20, respectively). Distribution into all the analyzed tissues (brain, lungs, liver, kidney, spleen, muscle, adipose tissue) was observed 3 h after single dose administration, the highest and lowest concentrations being reached in the adipose tissue and brain, respectively. The biliary excretion of the parent BP-14 and BP-20 compounds accounted for 4.81% and 10.6% of the doses, respectively, and renal excretion for <0.5% in both cases. The obtained results represent pilot knowledge for further development of a new generation of compounds with strong anticancer activities.


Subject(s)
2-Aminopurine/analogs & derivatives , Antineoplastic Agents/analysis , Antineoplastic Agents/chemistry , Cyclins/chemistry , Tandem Mass Spectrometry/methods , 2-Aminopurine/analysis , 2-Aminopurine/pharmacokinetics , Administration, Intravenous/methods , Animals , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/pharmacokinetics , Biological Availability , Calibration , Chromatography, High Pressure Liquid/methods , Hepatobiliary Elimination/drug effects , Humans , Limit of Detection , Male , Molecular Structure , Protein Kinase Inhibitors/administration & dosage , Protein Kinase Inhibitors/analysis , Protein Kinase Inhibitors/chemistry , Protein Kinase Inhibitors/pharmacokinetics , Rats , Rats, Wistar , Reproducibility of Results , Structure-Activity Relationship , Tissue Distribution/drug effects
2.
Am J Vet Res ; 77(8): 833-45, 2016 Aug.
Article in English | MEDLINE | ID: mdl-27463546

ABSTRACT

OBJECTIVES To determine, following oral administration of famciclovir, pharmacokinetic (PK) parameters for 2 of its metabolites (penciclovir and BRL42359) in plasma and tears of healthy cats so that famciclovir dosage recommendations for the treatment of herpetic disease can be optimized. ANIMALS 7 male domestic shorthair cats. PROCEDURES In a crossover study, each of 3 doses of famciclovir (30, 40, or 90 mg/kg) was administered every 8 or 12 hours for 3 days. Six cats were randomly assigned to each dosage regimen. Plasma and tear samples were obtained at predetermined times after famciclovir administration. Pharmacokinetic parameters were determined for BRL42359 and penciclovir by compartmental and noncompartmental methods. Pharmacokinetic-pharmacodynamic (PK-PD) indices were determined for penciclovir and compared among all dosage regimens. RESULTS Compared with penciclovir concentrations, BRL42359 concentrations were 5- to 11-fold greater in plasma and 4- to 7-fold greater in tears. Pharmacokinetic parameters and PK-PD indices for the 90 mg/kg regimens were superior to those for the 30 and 40 mg/kg regimens, regardless of dosing frequency. Penciclovir concentrations in tears ranged from 18% to 25% of those in plasma. Administration of 30 or 40 mg/kg every 8 hours achieved penciclovir concentrations likely to be therapeutic in plasma but not in tears. Penciclovir concentrations likely to be therapeutic in tears were achieved only with the two 90 mg/kg regimens. CONCLUSIONS AND CLINICAL RELEVANCE In cats, famciclovir absorption is variable and its metabolism saturable. Conversion of BRL42359 to penciclovir is rate limiting. The recommended dosage of famciclovir is 90 mg/kg every 12 hours for cats infected with feline herpesvirus.


Subject(s)
2-Aminopurine/analogs & derivatives , Acyclovir/analogs & derivatives , Antiviral Agents/pharmacokinetics , Cats/metabolism , Tears/metabolism , 2-Aminopurine/administration & dosage , 2-Aminopurine/blood , 2-Aminopurine/pharmacokinetics , Acyclovir/administration & dosage , Acyclovir/blood , Acyclovir/pharmacokinetics , Administration, Oral , Animals , Antiviral Agents/administration & dosage , Antiviral Agents/blood , Area Under Curve , Cross-Over Studies , Dose-Response Relationship, Drug , Famciclovir , Guanine , Male , Specific Pathogen-Free Organisms
3.
Mol Cancer Ther ; 14(2): 407-18, 2015 Feb.
Article in English | MEDLINE | ID: mdl-25519702

ABSTRACT

The clinical prognosis of pancreatic cancer remains rather disappointing despite tremendous efforts in exploring medical treatments in the past two decades. Development of more effective treatment strategies is still desperately needed to improve outcomes in patients with pancreatic cancer. SKLB261 is a multikinase inhibitor obtained recently through a lead optimization. In this investigation, we shall evaluate its anti-pancreatic cancer effects both in vitro and in vivo. SKLB261 is a multikinase inhibitor potently inhibiting EGFR, Src, and VEGFR2 kinases. It could significantly inhibit cell proliferation, migration, and invasion, and induce apoptosis in cellular assays of human pancreatic cancer cells that are sensitive or resistant to dasatinib and/or gemcitabine. Western blot analysis showed that SKLB261 inhibited the activation of EGFR and Src kinases as well as their downstream signaling proteins, including FAK, ERK, and STAT3. SKLB261 also showed potent antiangiogenic effects in transgenic zebrafish models. In vivo, SKLB261 displayed more potent antitumor activities than dasatinib, gemcitabine, or erlotinib in pancreatic cancer xenografts, including BxPC-3, PANC-1, AsPC-1, and HPAC. Furthermore, mice receiving SKLB261 therapy showed significant survival advantage compared with vehicle-treated and gemcitabine-treated groups in an experimental metastasis model of pancreatic cancer. These data, together with the good pharmacokinetic properties and low toxicity of this compound, provide a rationale for the ongoing clinical evaluation of SKLB261 in the treatment of pancreatic cancer.


Subject(s)
2-Aminopurine/analogs & derivatives , Drug Evaluation, Preclinical , ErbB Receptors/antagonists & inhibitors , Pancreatic Neoplasms/drug therapy , Piperazines/therapeutic use , Protein Kinase Inhibitors/therapeutic use , Vascular Endothelial Growth Factor Receptor-2/antagonists & inhibitors , src-Family Kinases/antagonists & inhibitors , 2-Aminopurine/chemistry , 2-Aminopurine/pharmacokinetics , 2-Aminopurine/pharmacology , 2-Aminopurine/therapeutic use , Angiogenesis Inhibitors/pharmacology , Angiogenesis Inhibitors/therapeutic use , Animals , Antineoplastic Agents/chemistry , Antineoplastic Agents/pharmacokinetics , Antineoplastic Agents/pharmacology , Antineoplastic Agents/therapeutic use , Apoptosis/drug effects , Cell Cycle Checkpoints/drug effects , Cell Line, Tumor , Cell Proliferation/drug effects , Disease Models, Animal , ErbB Receptors/metabolism , Female , G1 Phase/drug effects , Humans , Mice, Nude , Neoplasm Metastasis/pathology , Pancreatic Neoplasms/pathology , Piperazines/chemistry , Piperazines/pharmacokinetics , Piperazines/pharmacology , Protein Kinase Inhibitors/chemistry , Protein Kinase Inhibitors/pharmacokinetics , Protein Kinase Inhibitors/pharmacology , Rats, Sprague-Dawley , Recombinant Proteins/metabolism , Resting Phase, Cell Cycle/drug effects , Signal Transduction/drug effects , Vascular Endothelial Growth Factor Receptor-2/metabolism , Zebrafish , src-Family Kinases/metabolism
4.
Antimicrob Agents Chemother ; 57(12): 5820-9, 2013 Dec.
Article in English | MEDLINE | ID: mdl-24018260

ABSTRACT

The nucleoside analogues acyclovir (ACV) and famciclovir (FCV) reduce the frequency and severity of herpes simplex virus 2 (HSV-2) genital shedding, yet despite their high potency in vitro and a lack of induced drug resistance, frequent episodes of breakthrough mucosal shedding occur. We tested a published stochastic, spatial mathematical model of HSV-2 replication and spread, in concert with pharmacokinetic and pharmacodynamic equations, against virologic data from clinical trials of twice-daily acyclovir and famciclovir suppression. The model reproduced the key features of clinical trial data, including genital shedding episode rate, expansion and decay dynamics, and heterogeneous peak viral production and duration. In simulations, these agents shortened episode duration by limiting the extent of viral production by 1 to 2 log units and limiting the formation of secondary ulcers by ∼50%. However, drug concentrations were noninhibitory during 42% of the dosing cycle. Even if drug concentrations were high at episode initiation, prolonged episodes often ensued due to drug decay over ensuing hours and subsequent rebound of rapidly replicating HSV-2. The local CD8(+) T-cell density was more predictive of episode viral production (R(2) = 0.42) and duration (R(2) = 0.21) than the drug concentration at episode onset (R(2) = 0.14 and 0.05, respectively), though the model projected that an agent with an equivalent potency but a two times longer half-life would decrease shedding by 80% compared to that of standard twice-daily regimens. Therefore, long half-life is a key characteristic of any agent that might fully suppress HSV-2 reactivations.


Subject(s)
2-Aminopurine/analogs & derivatives , Acyclovir/pharmacokinetics , Antiviral Agents/pharmacokinetics , Herpesvirus 2, Human/physiology , Models, Statistical , 2-Aminopurine/pharmacokinetics , 2-Aminopurine/pharmacology , Acyclovir/pharmacology , Antiviral Agents/pharmacology , Biological Availability , CD8-Positive T-Lymphocytes/virology , Clinical Trials as Topic , Computer Simulation , Drug Administration Schedule , Famciclovir , Half-Life , Herpes Genitalis/drug therapy , Herpes Genitalis/virology , Herpesvirus 2, Human/drug effects , Humans , Lymphocyte Count , Viral Load/drug effects , Virus Replication/drug effects , Virus Shedding/drug effects
5.
Am J Vet Res ; 73(12): 1996-2000, 2012 Dec.
Article in English | MEDLINE | ID: mdl-23176429

ABSTRACT

OBJECTIVE: To determine plasma pharmacokinetics of penciclovir following oral and rectal administration of famciclovir to young Asian elephants (Elephas maximus). ANIMALS: 6 healthy Asian elephants (5 females and 1 male), 4.5 to 9 years old and weighing 1,646 to 2,438 kg. PROCEDURES: Famciclovir was administered orally or rectally in accordance with an incomplete crossover design. Three treatment groups, each comprising 4 elephants, received single doses of famciclovir (5 mg/kg, PO, or 5 or 15 mg/kg, rectally); there was a minimum 12-week washout period between subsequent famciclovir administrations. Serial blood samples were collected after each administration. Samples were analyzed for famciclovir and penciclovir with a validated liquid chromatography-mass spectroscopy assay. RESULTS: Famciclovir was tolerated well for both routes of administration and underwent complete biotransformation to the active metabolite, penciclovir. Mean maximum plasma concentration of penciclovir was 1.3 µg/mL at 1.1 hours after oral administration of 5 mg/kg. Similar results were detected after rectal administration of 5 mg/kg. Mean maximum plasma concentration was 3.6 µg/mL at 0.66 hours after rectal administration of 15 mg/kg; this concentration was similar to results reported for humans receiving 7 mg/kg orally. CONCLUSIONS AND CLINICAL RELEVANCE: Juvenile Asian elephants are susceptible to elephant endotheliotropic herpesvirus. Although most infections are fatal, case reports indicate administration of famciclovir has been associated with survival of 3 elephants. In Asian elephants, a dose of 8 to 15 mg of famciclovir/kg given orally or rectally at least every 8 hours may result in penciclovir concentrations that are considered therapeutic in humans.


Subject(s)
2-Aminopurine/analogs & derivatives , Acyclovir/analogs & derivatives , Antiviral Agents/pharmacokinetics , Elephants/metabolism , 2-Aminopurine/administration & dosage , 2-Aminopurine/blood , 2-Aminopurine/pharmacokinetics , Acyclovir/administration & dosage , Acyclovir/blood , Acyclovir/pharmacokinetics , Administration, Oral , Administration, Rectal , Animals , Antiviral Agents/administration & dosage , Antiviral Agents/blood , Area Under Curve , Chromatography, Liquid , Cross-Over Studies , Famciclovir , Female , Guanine , Half-Life , Male , Mass Spectrometry
6.
Am J Vet Res ; 73(7): 1092-9, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22738064

ABSTRACT

OBJECTIVE: To investigate the pharmacokinetics of penciclovir in healthy cats following oral administration of famciclovir or IV infusion of penciclovir. ANIMALS: 6 cats. PROCEDURES: Cats received famciclovir (40 [n = 3] or 90 [3] mg/kg, PO, once) in a balanced crossover-design study; the alternate dose was administered after a ≥ 2-week washout period. After another washout period (≥ 4 weeks), cats received an IV infusion of penciclovir (10 mg/kg delivered over 1 hour). Plasma penciclovir concentrations were analyzed via liquid chromatography-mass spectrometry at fixed time points after drug administration. RESULTS: Mean ± SD maximum plasma concentration (C(max)) of penciclovir following oral administration of 40 and 90 mg of famciclovir/kg was 1.34 ± 0.33 µg/mL and 1.28 ± 0.42 µg/mL and occurred at 2.8 ± 1.8 hours and 3.0 ± 1.1 hours, respectively; penciclovir elimination half-life was 4.2 ± 0.6 hours and 4.8 ± 1.4 hours, respectively; and penciclovir bioavailability was 12.5 ± 3.0% and 7.0 ± 1.8%, respectively. Following IV infusion of penciclovir (10 mg/kg), mean ± SD penciclovir clearance, volume of distribution, and elimination half-life were 4.3 ± 0.8 mL/min/kg, 0.6 ± 0.1 L/kg, and 1.9 ± 0.4 hours, respectively. CONCLUSIONS AND CLINICAL RELEVANCE: Penciclovir pharmacokinetics following oral administration of famciclovir were nonlinear within the dosage range studied, likely because of saturation of famciclovir metabolism. Oral administration of famciclovir at 40 or 90 mg/kg produced similar C(max) and time to C(max) values. Therefore, the lower dose may have similar antiviral efficacy to that proven for the higher dose.


Subject(s)
2-Aminopurine/analogs & derivatives , Acyclovir/analogs & derivatives , Antiviral Agents/pharmacokinetics , Cats/metabolism , Prodrugs/pharmacokinetics , 2-Aminopurine/administration & dosage , 2-Aminopurine/blood , 2-Aminopurine/pharmacokinetics , Acyclovir/administration & dosage , Acyclovir/blood , Acyclovir/pharmacokinetics , Administration, Oral , Animals , Antiviral Agents/administration & dosage , Antiviral Agents/blood , Area Under Curve , Biological Availability , Cross-Over Studies , Famciclovir , Female , Guanine , Half-Life , Male , Prodrugs/administration & dosage
7.
Vet Ophthalmol ; 15(5): 299-306, 2012 Sep.
Article in English | MEDLINE | ID: mdl-22339892

ABSTRACT

OBJECTIVE: To validate a means of collecting tears from cats, develop an assay for quantifying famciclovir and penciclovir in tears, and to assess famciclovir and penciclovir concentrations and pharmacokinetics in the tears of cats being treated orally with famciclovir for suspected herpetic disease. ANIMALS: Seven client-owned cats. PROCEDURES: Cats were treated orally with a median (range) dose of 40 (39-72) mg of famciclovir/kg three times daily for at least 24 h. At various time points following famciclovir administration, tear samples were collected using Schirmer tear test strips. Tear famciclovir and penciclovir concentrations were measured using liquid chromatography-mass spectrometry, and concentration-time profiles were analyzed noncompartmentally. The relationship between famciclovir dose and tear penciclovir concentration near its maximum was evaluated using least squares linear regression. RESULTS: Maximum tear famciclovir concentration of 0.305 µg/mL occurred at 2.64 h; elimination half-life was 2.28 h. Maximum tear penciclovir concentration (0.981 µg/mL) occurred 2.25 h following oral administration of famciclovir; elimination half-life was 2.77 h. A significant positive correlation was noted between famciclovir dose and tear penciclovir concentration at various time points between 0.5 and 3.75 h following drug administration (P = 0.025). Tear penciclovir concentration exceeded the concentration shown to have in vitro efficacy against feline herpesvirus (FHV-1) (0.304 µg/mL) in about half of samples collected. CONCLUSIONS: Oral administration of 40 mg of famciclovir/kg to cats resulted in a tear penciclovir concentration-time profile that approximated the plasma penciclovir concentration-time profile and frequently achieved a penciclovir concentration at the ocular surface likely to be effective against FHV-1.


Subject(s)
2-Aminopurine/analogs & derivatives , Acyclovir/analogs & derivatives , Antiviral Agents/pharmacokinetics , Eye Diseases/veterinary , Herpesviridae Infections/veterinary , Tears/chemistry , 2-Aminopurine/administration & dosage , 2-Aminopurine/chemistry , 2-Aminopurine/pharmacokinetics , 2-Aminopurine/therapeutic use , Acyclovir/chemistry , Acyclovir/pharmacokinetics , Acyclovir/therapeutic use , Administration, Oral , Animals , Antiviral Agents/chemistry , Antiviral Agents/therapeutic use , Cats , Dose-Response Relationship, Drug , Eye Diseases/drug therapy , Eye Diseases/virology , Famciclovir , Guanine , Herpesviridae Infections/drug therapy , Pilot Projects , Specimen Handling/methods , Specimen Handling/veterinary
8.
Pediatr Infect Dis J ; 30(6): 525-8, 2011 Jun.
Article in English | MEDLINE | ID: mdl-21178655

ABSTRACT

An open-label study evaluated the safety (n = 53) and pharmacokinetics (n = 8) of single-dose therapy with 1500 mg famciclovir (prodrug of penciclovir) for recurrent herpes labialis in adolescents. Mean Cmax, mean AUC0-∞, and clearance for penciclovir were 9.37 µg/mL, 31.8 µg · h/mL, and 38.2 L/h, respectively, and within the range extrapolated from data in adults. Adverse events were generally mild and transient.


Subject(s)
2-Aminopurine/analogs & derivatives , Antiviral Agents/adverse effects , Antiviral Agents/pharmacokinetics , Herpes Labialis/drug therapy , 2-Aminopurine/administration & dosage , 2-Aminopurine/adverse effects , 2-Aminopurine/pharmacokinetics , Adolescent , Antiviral Agents/administration & dosage , Child , Famciclovir , Female , Humans , Male , Metabolic Clearance Rate , Recurrence , Serum/chemistry
9.
RNA ; 16(12): 2427-34, 2010 Dec.
Article in English | MEDLINE | ID: mdl-20962040

ABSTRACT

2-Aminopurine (2AP) is a fluorescent adenine analog that probes mainly base stacking in nucleic acids. We labeled the loop or the stem of the RNA hairpin gacUACGguc with 2AP to study folding thermodynamics and kinetics at both loci. Thermal melts and fast laser temperature jumps detected by 2AP fluorescence monitored the stability and folding/unfolding kinetics. The observed thermodynamic and kinetic traces of the stem and loop mutants, though strikingly different at a first glance, can be fitted to the same free-energy landscape. The differences between the two probe locations arise because base stacking decreases upon unfolding in the stem, whereas it increases in the loop. We conclude that 2AP is a conservative adenine substitution for mapping out the contributions of different RNA structural elements to the overall folding process. Molecular dynamics (MD) totaling 0.6 µsec were performed to look at the conformations populated by the RNA at different temperatures. The combined experimental data, and MD simulations lead us to propose a minimal four-state free-energy landscape for the RNA hairpin. Analysis of this landscape shows that a sequential folding model is a good approximation for the full folding dynamics. The frayed state formed initially from the native state is a heterogeneous ensemble of structures whose stem is frayed either from the end or from the loop.


Subject(s)
Nucleic Acid Conformation , RNA/chemistry , 2-Aminopurine/chemistry , 2-Aminopurine/pharmacokinetics , Fluorescence , Kinetics , Models, Biological , Models, Molecular , Molecular Dynamics Simulation , Nucleic Acid Denaturation , RNA/metabolism , Temperature , Thermodynamics
10.
Expert Opin Drug Saf ; 9(4): 643-58, 2010 Jul.
Article in English | MEDLINE | ID: mdl-20429777

ABSTRACT

IMPORTANCE OF THE FIELD: Famciclovir is the prodrug of penciclovir, a guanosine analogue that inhibits viruses of the alpha sub-family of the Herpesviridae, as well as hepatitis B virus. It is indicated for management of mucocutaneous herpes simplex virus disease and acute herpes zoster, and has been investigated for management of hepatitis B virus infection. AREAS COVERED IN THIS REVIEW: Data for this review were identified by searches of papers published in English on Medline and Scopus, spanning the years 1975 through 1 February 2010 with the key words: 'famciclovir', 'famvir', 'penciclovir', 'herpes', 'oral', 'genital', 'varicella', 'zoster' and 'virus' in association with 'safety', 'toxicity', 'tolerability', 'efficacy' and 'indications'. Relevant references were also obtained from articles acquired through the search strategy. WHAT THE READER WILL GAIN: Readers are also provided with up-to-date information on the use of famciclovir for infections due to herpes simplex, varicella zoster and hepatitis B viruses. Clinical data pertaining to the safety and tolerability of famciclovir are also reviewed. TAKE HOME MESSAGE: Famciclovir is a safe, convenient, and well-tolerated drug when used for its approved indications. The most common side effects indicated in the majority of studies were headache and nausea. Data for its use in childhood and pregnancy are limited.


Subject(s)
2-Aminopurine/analogs & derivatives , Antiviral Agents/therapeutic use , Hepatitis B/drug therapy , Herpesviridae Infections/drug therapy , 2-Aminopurine/adverse effects , 2-Aminopurine/pharmacokinetics , 2-Aminopurine/pharmacology , 2-Aminopurine/therapeutic use , Antiviral Agents/adverse effects , Antiviral Agents/pharmacokinetics , Antiviral Agents/pharmacology , Famciclovir , Female , Hepatitis B virus/drug effects , Herpesvirus 3, Human/drug effects , Humans , Male , Pregnancy , Pregnancy Complications, Infectious/drug therapy , Simplexvirus/drug effects , Treatment Outcome
11.
Antimicrob Agents Chemother ; 54(5): 2032-41, 2010 May.
Article in English | MEDLINE | ID: mdl-20160046

ABSTRACT

A multicenter, open-label study evaluated the single-dose pharmacokinetics and safety of a pediatric oral famciclovir (prodrug of penciclovir) formulation in infants aged 1 to 12 months with suspicion or evidence of herpes simplex virus infection. Individualized single doses of famciclovir based on the infant's body weight ranged from 25 to 175 mg. Eighteen infants were enrolled (1 to <3 months old [n = 8], 3 to <6 months old [n = 5], and 6 to 12 months old [n = 5]). Seventeen infants were included in the pharmacokinetic analysis; one infant experienced immediate emesis and was excluded. Mean C(max) and AUC(0-6) values of penciclovir in infants <6 months of age were approximately 3- to 4-fold lower than those in the 6- to 12-month age group. Specifically, mean AUC(0-6) was 2.2 microg h/ml in infants aged 1 to <3 months, 3.2 microg h/ml in infants aged 3 to <6 months, and 8.8 microg h/ml in infants aged 6 to 12 months. These data suggested that the dose administered to infants <6 months was less than optimal. Eight (44.4%) infants experienced at least one adverse event with gastrointestinal events reported most commonly. An updated pharmacokinetic analysis was conducted, which incorporated the data in infants from the present study and previously published data on children 1 to 12 years of age. An eight-step dosing regimen was derived that targeted exposure in infants and children 6 months to 12 years of age to match the penciclovir AUC seen in adults after a 500-mg dose of famciclovir.


Subject(s)
2-Aminopurine/analogs & derivatives , Antiviral Agents/pharmacokinetics , Herpes Simplex/drug therapy , Models, Biological , 2-Aminopurine/administration & dosage , 2-Aminopurine/adverse effects , 2-Aminopurine/pharmacokinetics , Acyclovir/analogs & derivatives , Acyclovir/pharmacokinetics , Administration, Oral , Antiviral Agents/administration & dosage , Antiviral Agents/adverse effects , Body Weight , Capsules , Child , Child, Preschool , Famciclovir , Female , Guanine , Humans , Infant, Newborn , Male
12.
J Vet Med Sci ; 72(3): 357-61, 2010 Mar.
Article in English | MEDLINE | ID: mdl-19959884

ABSTRACT

We investigated the pharmacokinetics of penciclovir after oral administration of its prodrug famciclovir to horses. Following an oral dose of famciclovir at 20 mg/kg, maximum plasma concentrations of penciclovir occurred between 0.75 and 1.5 hr (mean 0.94 + or - 0.38 hr) after dosing and were in the range 2.22 to 3.56 microg/ml (mean 2.87 + or - 0.61 microg/ml). The concentrations of penciclovir declined in a biphasic manner after the peak concentration was attained. The mean half-life of the rapid elimination phase was 1.73 + or - 0.34 hr whereas that of the slow elimination phase was 34.34 + or - 13.93 hr. These pharmacokinetic profiles observed were similar to those of another antiherpesvirus drug, acyclovir, previously reported in horses following oral dosing of its prodrug valacyclovir.


Subject(s)
2-Aminopurine/analogs & derivatives , Acyclovir/analogs & derivatives , 2-Aminopurine/administration & dosage , 2-Aminopurine/blood , 2-Aminopurine/pharmacokinetics , Acyclovir/blood , Acyclovir/pharmacokinetics , Administration, Oral , Animals , Antiviral Agents/blood , Antiviral Agents/pharmacokinetics , Area Under Curve , Famciclovir , Guanine , Half-Life , Herpesviridae Infections/drug therapy , Herpesviridae Infections/veterinary , Herpesvirus 1, Equid/drug effects , Horse Diseases/drug therapy , Horse Diseases/virology , Horses
13.
Br J Clin Pharmacol ; 68(4): 546-60, 2009 Oct.
Article in English | MEDLINE | ID: mdl-19843058

ABSTRACT

AIMS: To develop a population pharmacokinetic model for penciclovir (famciclovir is a prodrug of penciclovir) in adults and children and suggest an appropriate dose for children. Furthermore, to develop a limited sampling design based on sampling windows for three different paediatric age groups (1-2, 2-5 and 5-12 years) using an adequate number of subjects for future pharmacokinetic studies. METHODS: Penciclovir plasma data from six different adult and paediatric studies were supplied by Novartis. Population pharmacokinetic modelling was undertaken in NONMEM version VI. Simulations in MATLAB were used to select an oral paediatric dose that gives similar exposure to 500 mg in adults. Optimal sampling times and sampling windows were obtained in MATLAB and simulations in NONMEM were used to select adequate sample sizes for three paediatric age groups. RESULTS: A two-compartment, first-order absorption model with an absorption lag time, allometric weight models on V(1), V(2) and Q, and an allometric weight model, age and creatinine clearance as covariates on CL adequately describe the pharmacokinetics of penciclovir in adults and children. Estimated CL (l h(-1) 70 kg(-1)) and V(ss) (l.70 kg(-1)) were 31.2 and 83.1, respectively. An oral dose of 10 mg kg(-1) body weight in children was predicted to give similar exposure as 500 mg in adults. A single sampling windows design (0.25-0.4, 0.5-1, 1.25-1.75, 2.75-3.5 and 7.25-8 h) for five samples per subject and 10 subjects in each of the paediatric age groups is recommended for future studies. CONCLUSIONS: A population pharmacokinetic model of penciclovir in adults and children has been developed. A prospective study design, including dose adjustment, cohort size and blood sampling design has been recommended.


Subject(s)
2-Aminopurine/analogs & derivatives , Antiviral Agents/pharmacokinetics , Dose-Response Relationship, Drug , 2-Aminopurine/administration & dosage , 2-Aminopurine/pharmacokinetics , Adult , Age Factors , Antiviral Agents/administration & dosage , Area Under Curve , Body Weight/physiology , Child , Child, Preschool , Famciclovir , Female , Humans , Infant , Male , Models, Biological , Research Design , Time Factors
14.
Am J Ophthalmol ; 148(1): 38-42.e1, 2009 Jul.
Article in English | MEDLINE | ID: mdl-19375688

ABSTRACT

PURPOSE: To determine the vitreous penetration of penciclovir (Denavir; GlaxoSmithKline, Philadelphia, Pennsylvania, USA) after oral administration of the prodrug famciclovir (Famvir; Novartis Pharmaceuticals Corp, East Hanover, New Jersey, USA). DESIGN: Prospective interventional case series. METHODS: Ten patients undergoing elective pars plana vitrectomy at a single institution were enrolled to take 3 oral doses of famciclovir 500 mg the day preceding surgery and a fourth dose on the morning of surgery. Blood and undiluted vitreous samples were acquired from each patient during surgery. High-performance liquid chromatography was used to determine the concentration of penciclovir in each sample. Exclusion criteria included prior vitrectomy, compromised blood-retina barrier, renal or hepatic disease, human immunodeficiency virus infection, bone marrow or renal transplantation, pregnancy or breastfeeding, history of adverse reaction or allergy to famciclovir or penciclovir, and antiviral, probenecid, or cimetidine use within 1 month of surgery. RESULTS: Ten eyes of 10 patients ranging in age from 26 to 82 were included. All patients had normal renal and hepatic function as determined by history and laboratory values. Mean serum penciclovir concentration +/- standard deviation was 4.45 +/- 1.31 microg/ml (range, 2.51 to 6.34 microg/ml). Mean vitreous penciclovir concentration was 1.21 +/- 0.38 microg/ml (range, 0.39 to 1.88 microg/ml). Mean vitreous-to-serum concentration ratio of penciclovir was 0.28 +/- 0.09 (range, 0.16 to 0.41). CONCLUSIONS: Oral administration of famciclovir results in vitreous concentrations of penciclovir within the inhibitory ranges for herpes simplex 1, herpes simplex 2, and varicella zoster virus. Oral famciclovir may be a reasonable alternative to intravenous acyclovir (Zovirax; GlaxoSmithKline) in the treatment of acute retinal necrosis, especially in cases of acyclovir resistance or patient inability to tolerate prolonged intravenous treatment.


Subject(s)
2-Aminopurine/analogs & derivatives , Antiviral Agents/pharmacokinetics , Prodrugs/pharmacokinetics , Vitreous Body/metabolism , 2-Aminopurine/blood , 2-Aminopurine/pharmacokinetics , Administration, Oral , Adult , Aged , Aged, 80 and over , Antiviral Agents/blood , Biological Availability , Chromatography, High Pressure Liquid , Eye Infections, Viral/drug therapy , Famciclovir , Female , Humans , Male , Middle Aged , Prospective Studies , Retinal Necrosis Syndrome, Acute/drug therapy , Retinal Necrosis Syndrome, Acute/virology , Vitrectomy
15.
Antimicrob Agents Chemother ; 53(5): 1912-20, 2009 May.
Article in English | MEDLINE | ID: mdl-19273678

ABSTRACT

Two multicenter, open-label, single-arm, two-phase studies evaluated single-dose pharmacokinetics and single- and multiple-dose safety of a pediatric oral famciclovir formulation (prodrug of penciclovir) in children aged 1 to 12 years with suspicion or evidence of herpes simplex virus (HSV) or varicella-zoster virus (VZV) infection. Pooled pharmacokinetic data were generated after single doses in 51 participants (approximately 12.5 mg/kg of body weight [BW] for children weighing < 40 kg and 500 mg for children weighing > or = 40 kg). The average systemic exposure to penciclovir was similar (6- to 12-year-olds) or slightly lower (1- to < 6-year-olds) than that in adults receiving a 500-mg dose of famciclovir (historical data). The apparent clearance of penciclovir increased with BW in a nonlinear manner, proportional to BW(0.696). An eight-step weight-based dosing regimen was developed to optimize exposure in smaller children and was used in the 7-day multiple-dose safety phases of both studies, which enrolled 100 patients with confirmed/suspected viral infections. Twenty-six of 47 (55.3%) HSV-infected patients who received famciclovir twice a day and 24 of 53 (45.3%) VZV-infected patients who received famciclovir three times a day experienced at least one adverse event. Most adverse events were gastrointestinal in nature. Exploratory analysis following 7-day famciclovir dosing regimen showed resolution of symptoms in most children with active HSV (19/21 [90.5%]) or VZV disease (49/53 [92.5%]). Famciclovir formulation (sprinkle capsules in OraSweet) was acceptable to participants/caregivers. In summary, we present a weight-adjusted dosing schedule for children that achieves systemic exposures similar to those for adults given the 500-mg dose.


Subject(s)
2-Aminopurine/analogs & derivatives , Antiviral Agents , Chickenpox/drug therapy , Herpes Simplex/drug therapy , Herpesvirus 3, Human/drug effects , Simplexvirus/drug effects , 2-Aminopurine/administration & dosage , 2-Aminopurine/adverse effects , 2-Aminopurine/pharmacokinetics , Acyclovir/administration & dosage , Antiviral Agents/administration & dosage , Antiviral Agents/adverse effects , Antiviral Agents/pharmacokinetics , Chickenpox/virology , Child , Child, Preschool , Drug Administration Schedule , Drug Therapy, Combination , Famciclovir , Female , Herpes Simplex/virology , Humans , Infant , Male , Treatment Outcome
16.
J Clin Pharmacol ; 47(7): 877-89, 2007 Jul.
Article in English | MEDLINE | ID: mdl-17526857

ABSTRACT

Emtricitabine is a potent nucleoside reverse transcriptase inhibitor approved as a once-daily drug in combination with other antiretroviral agents for the treatment of HIV infection. Several phase I studies were conducted in healthy volunteers over the course of clinical development to evaluate whether pharmacokinetic drug-drug interactions exist between emtricitabine and other nucleoside antivirals that are extensively eliminated by renal excretion. Potential interactions with stavudine and famciclovir were evaluated in single-dose studies, whereas interactions with zidovudine and its major metabolite, zidovudine glucuronide, were evaluated in a multiple-dose study. Plasma pharmacokinetic profiles and, in some studies, urinary excretion data were evaluated when each drug was administered alone and in combination with emtricitabine. Safety and plasma pharmacokinetic profiles of each drug administered alone or with emtricitabine were consistent with historical data. Statistical analyses indicated that there were no significant interactions between emtricitabine and these 3 nucleoside antivirals.


Subject(s)
2-Aminopurine/analogs & derivatives , Anti-HIV Agents/pharmacokinetics , Deoxycytidine/analogs & derivatives , Reverse Transcriptase Inhibitors/pharmacokinetics , Stavudine/pharmacokinetics , Zidovudine/pharmacokinetics , 2-Aminopurine/administration & dosage , 2-Aminopurine/blood , 2-Aminopurine/pharmacokinetics , 2-Aminopurine/therapeutic use , Adolescent , Adult , Anti-HIV Agents/administration & dosage , Anti-HIV Agents/blood , Anti-HIV Agents/therapeutic use , Area Under Curve , Cross-Over Studies , Deoxycytidine/administration & dosage , Deoxycytidine/blood , Deoxycytidine/pharmacokinetics , Deoxycytidine/therapeutic use , Drug Interactions , Drug Therapy, Combination , Emtricitabine , Famciclovir , Female , Humans , Male , Middle Aged , Reverse Transcriptase Inhibitors/administration & dosage , Reverse Transcriptase Inhibitors/blood , Reverse Transcriptase Inhibitors/therapeutic use , Stavudine/administration & dosage , Stavudine/blood , Stavudine/therapeutic use , Zidovudine/administration & dosage , Zidovudine/blood , Zidovudine/therapeutic use
17.
Drugs ; 66(18): 2397-416, 2006.
Article in English | MEDLINE | ID: mdl-17181386

ABSTRACT

Famciclovir (Famvir) is the oral prodrug of penciclovir, an agent that has demonstrated antiviral activity against herpes simplex viruses, type 1 (HSV-1) and 2 (HSV-2) [which cause orolabial and/or genital herpes simplex], and against varicella zoster virus (VZV) [a reactivation of which leads to herpes zoster]. Famciclovir has efficacy similar to that of aciclovir (in immunocompetent or immunocompromised patients) or valaciclovir (in immunocompetent patients) in the treatment of herpes zoster, and efficacy similar to aciclovir in the treatment of first or recurrent episodes of genital herpes (in immunocompetent or immunocompromised patients). Famciclovir also has efficacy in the suppression of recurrent episodes of genital herpes, and in the treatment of orolabial herpes, in immunocompetent patients. As such, famciclovir is a well tolerated first-line option for the treatment of herpes zoster and the treatment and suppression of genital herpes, and is approved for the treatment of recurrent orolabial herpes. Convenient patient-initiated single-day (for recurrent genital herpes) and single-dose (for orolabial herpes) dosage regimens may contribute to treatment compliance, patient acceptability and subsequent treatment outcomes.


Subject(s)
2-Aminopurine/analogs & derivatives , Antiviral Agents/therapeutic use , Herpes Genitalis/drug therapy , Herpes Labialis/drug therapy , Herpes Zoster/drug therapy , 2-Aminopurine/administration & dosage , 2-Aminopurine/adverse effects , 2-Aminopurine/pharmacokinetics , 2-Aminopurine/therapeutic use , Animals , Antiviral Agents/administration & dosage , Antiviral Agents/adverse effects , Antiviral Agents/pharmacokinetics , Famciclovir , Humans , Recurrence , Treatment Outcome
18.
Antivir Chem Chemother ; 15(5): 251-3, 2004 Sep.
Article in English | MEDLINE | ID: mdl-15535046

ABSTRACT

The herpesviruses continue to produce considerable morbidity in man. Once infected with herpes simplex (HSV), the virus remains dormant within the nervous system and may reactivate if provoked by stress, trauma and/or other factors. To date, there is no cure, but antiviral medication can reduce duration and severity of symptoms and prophylaxis can suppress recurrent episodes of disease. The second-generation guanosine nucleosides, acyclovir and penciclovir, are effective inhibitors with low toxicity; both, however, have relatively low oral bioavailability. Subsequently, the orally bioavailable prodrugs valaciclovir and famciclovir have been introduced. These compounds offer high oral bioavailabilty and deliver acyclovir and penciclovir, respectively, to the target cells by means of more convenient dosing schedules. This short review points to recent experience with famciclovir in the management of HSV and varicella-zoster virus.


Subject(s)
2-Aminopurine/analogs & derivatives , 2-Aminopurine/therapeutic use , Acyclovir/analogs & derivatives , Antiviral Agents/therapeutic use , Prodrugs/therapeutic use , 2-Aminopurine/pharmacokinetics , Acyclovir/pharmacology , Antiviral Agents/pharmacokinetics , Biological Availability , Clinical Trials as Topic , Famciclovir , Guanine , Herpes Genitalis/drug therapy , Herpes Genitalis/metabolism , Herpes Zoster/drug therapy , Herpes Zoster/metabolism , Humans , Male , Nervous System/drug effects , Nervous System/metabolism , Nervous System/virology , Prodrugs/pharmacokinetics
20.
J Wildl Dis ; 36(1): 1-12, 2000 Jan.
Article in English | MEDLINE | ID: mdl-10682740

ABSTRACT

The unique clinical and pathological findings in nine Asian (Elephas maximus) and two African (Loxodonta africana) elephants from North American Zoos with a highly fatal disease caused by novel endotheliotropic herpesviruses are described. Identification of the viruses by molecular techniques and some epidemiological aspects of the disease were previously reported. Consensus primer polymerase chain reaction (PCR) combined with sequencing yielded molecular evidence that confirmed the presence of two novel but related herpesviruses associated with the disease, one in Asian elephants and the second in African elephants. Disease onset was acute, with lethargy, edema of the head and thoracic limbs, oral ulceration and cyanosis of the tongue followed by death of most animals in 1 to 7 days. Pertinent laboratory findings in two of three clinically evaluated animals included lymphocytopenia and thrombocytopenia. Two affected young Asian elephants recovered after a 3 to 4 wk course of therapy with the anti-herpesvirus drug famciclovir. Necropsy findings in the fatal cases included pericardial effusion and extensive petechial hemorrhages in the heart and throughout the peritoneal cavity, hepatomegaly, cyanosis of the tongue, intestinal hemorrhage, and ulceration. Histologically, there were extensive microhemorrhages and edema throughout the myocardium and mild, subacute myocarditis. Similar hemorrhagic lesions with inflammation were evident in the tongue, liver, and large intestine. Lesions in these target organs were accompanied by amphophilic to basophilic intranuclear viral inclusion bodies in capillary endothelial cells. Transmission electron microscopy of the endothelial inclusion bodies revealed 80 to 92 nm diameter viral capsids consistent with herpesvirus morphology. The short course of the herpesvirus infections, with sudden deaths in all but the two surviving elephants, was ascribed to acute cardiac failure attributed to herpesvirus-induced capillary injury with extensive myocardial hemorrhage and edema.


Subject(s)
Animals, Zoo , Elephants , Endothelium, Vascular/virology , Herpesviridae Infections/veterinary , Herpesviridae/isolation & purification , 2-Aminopurine/analogs & derivatives , 2-Aminopurine/pharmacokinetics , 2-Aminopurine/therapeutic use , Acyclovir/analogs & derivatives , Acyclovir/blood , Animals , Antiviral Agents/blood , Antiviral Agents/pharmacokinetics , Antiviral Agents/therapeutic use , DNA, Viral/blood , DNA, Viral/chemistry , DNA, Viral/isolation & purification , Famciclovir , Female , Guanine , Herpesviridae/genetics , Herpesviridae/immunology , Herpesviridae Infections/drug therapy , Herpesviridae Infections/pathology , Herpesviridae Infections/virology , Liver/pathology , Lung/pathology , Lung/virology , Male , Myocardium/pathology , Myocardium/ultrastructure , North America , Polymerase Chain Reaction/veterinary , Prodrugs/pharmacokinetics , Prodrugs/therapeutic use , Retrospective Studies , Tongue/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...